This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Benfotiamine is a derivative of thiamine thought to be useful in the management of diabetic neuropathy, although evidence is lacking.

Generic Name
Benfotiamine
DrugBank Accession Number
DB11748
Background

Benfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2.

Type
Small Molecule
Groups
Approved, Experimental
Structure
Thumb
Weight
Average: 466.45
Monoisotopic: 466.107592649
Chemical Formula
C19H23N4O6PS
Synonyms
  • Benfotiamina
  • Benfotiamine
  • Benphothiamine
  • Benzoylthiamine monophosphate
  • S-benzoylthiamine monophosphate
External IDs
  • 8088 C.B.
  • 8088-CB
  • 8088CB

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
MILGAMMA MONO 150Tablet, coated150 mgOralบริษัท ซิลลิค ฟาร์มา จำกัด2018-06-18Not applicableThailand flag

Categories

ATC Codes
A11DA03 — Benfotiamine
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Y92OUS2H9B
CAS number
22457-89-2
InChI Key
BTNNPSLJPBRMLZ-LGMDPLHJSA-N
InChI
InChI=1S/C19H23N4O6PS/c1-13(23(12-24)11-16-10-21-14(2)22-18(16)20)17(8-9-29-30(26,27)28)31-19(25)15-6-4-3-5-7-15/h3-7,10,12H,8-9,11H2,1-2H3,(H2,20,21,22)(H2,26,27,28)/b17-13-
IUPAC Name
{[(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]formamido}-3-[(Z)-benzoylsulfanyl]pent-3-en-1-yl]oxy}phosphonic acid
SMILES
C\C(N(CC1=CN=C(C)N=C1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)C1=CC=CC=C1

References

General References
  1. Worwag Pharma: Milgamma Protekt (benfotiamine) film-coated tablets [Link]
PubChem Compound
3032771
PubChem Substance
347828105
ChemSpider
2297665
RxNav
18891
ChEBI
41039
ChEMBL
CHEMBL4303665
ZINC
ZINC000002015559
Wikipedia
Benfotiamine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionEndothelial Dysfunction / Type 2 Diabetes Mellitus1
4CompletedTreatmentAlcohol Dependency1
4CompletedTreatmentDiabetic Nephropathy1
4Unknown StatusPreventionType 2 Diabetes Mellitus1
3CompletedPreventionHealthy Subjects (HS)1
3Unknown StatusTreatmentDiabetic Neuropathies1
2CompletedTreatmentAlzheimer's Disease (AD)1
1, 2CompletedTreatmentType 1 Diabetes Mellitus1
1, 2WithdrawnTreatmentDiabetic Neuropathy, Painful; Diabetic Neuropathies1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, coatedOral150 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.04 mg/mLALOGPS
logP0.89ALOGPS
logP-2.2ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)0.71ChemAxon
pKa (Strongest Basic)7.37ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area155.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity121.54 m3·mol-1ChemAxon
Polarizability43.14 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at October 20, 2016 20:44 / Updated at May 07, 2021 21:07